Prognostic and predictive value of immunological parameters for chemoradioimmunotherapy in patients with pancreatic adenocarcinoma

BACKGROUND: Chemoradioimmunotherapy of patients with pancreatic adenocarcinoma from the CapRI trial did not show any benefit of interferon-α in addition to a 5-fluorouracil (5FU)-based treatment. The aim of this study was to identify immunological parameters in patients from this trial to be used fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Karakhanova, S, Ryschich, E, Mosl, B, Harig, S, Jäger, D, Schmidt, J, Hartwig, W, Werner, J, Bazhin, A V
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366903/
https://www.ncbi.nlm.nih.gov/pubmed/25742476
http://dx.doi.org/10.1038/bjc.2015.72

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366903/
https://www.ncbi.nlm.nih.gov/pubmed/25742476
http://dx.doi.org/10.1038/bjc.2015.72

Ejemplares similares